Our findings provide important further evidence on psychological, functional, and structural levels to support VIP as a potential target for therapeutic investigation in anxiety and depression, and in disorders of the gut-brain axis with high psychological comorbidities. This evidence concerns the gene VIP and depressive symptom measurement.